Jun 01, 2021

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.

"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."

Read the full article here. 

 This contains certain forward-looking statements.